How has been the historical performance of Vanta Bioscience?

Answer:The historical performance of Vanta Bioscience shows fluctuating net sales and profitability over the years, with a notable decline in recent periods.

Breakdown:
Vanta Bioscience's net sales for March 2024 were reported at 9.72 Cr, an increase from 6.28 Cr in March 2023, but a slight decrease from 9.69 Cr in March 2022. The total operating income mirrored this trend, reaching 9.72 Cr in March 2024. However, the company faced challenges with total expenditure, which was 8.41 Cr in March 2024, down from 8.67 Cr in March 2023. Operating profit (PBDIT) showed a recovery to 1.42 Cr in March 2024, compared to a loss of 1.70 Cr in the previous year. Despite this, the company reported a profit before tax of -2.54 Cr in March 2024, an improvement from -6.30 Cr in March 2023, leading to a net profit of -2.32 Cr for March 2024, also better than the -6.48 Cr reported in March 2023. The balance sheet reflects total liabilities of 85.40 Cr in March 2024, slightly up from 84.71 Cr in March 2023, while total assets also increased to 85.40 Cr. The cash flow statement indicates a cash flow from operating activities of 2.00 Cr in March 2024, a positive shift from 0.00 Cr in March 2023, although the net cash inflow/outflow remained at 0.00 Cr for both years. Overall, Vanta Bioscience's financial performance indicates a gradual recovery in sales and operating profit, despite ongoing net losses.